共 4 条
Polarisation of a T-helper cell immune response by activation of dendritic cells with CpG-containing oligonucleotides: a potential therapeutic regime for bladder cancer immunotherapy
被引:0
|作者:
H Atkins
B R Davies
J A Kirby
J D Kelly
机构:
[1] Northern Institute for Cancer Research,Department of Oncology
[2] School of Surgical and Reproductive Sciences,undefined
[3] Faculty of Medical Sciences,undefined
[4] University of Newcastle,undefined
[5] University of Cambridge,undefined
来源:
British Journal of Cancer
|
2003年
/
89卷
关键词:
bladder cancer;
BCG immunotherapy;
CpG-oligonucleotides;
toll-like receptor;
D O I:
暂无
中图分类号:
学科分类号:
摘要:
Intravesical bacillus Calmette–Guerin (BCG) is a treatment for transitional cell carcinoma (TCC) and carcinoma in situ (cis) of the urinary bladder, but some patients remain refractory. The mechanism of cancer clearance is not known, but T cells are thought to play a contributory role. Tissue dendritic cells (DCs) are known to initiate antigen-specific immune responses following activation of receptors, which recognise molecular patterns on the surface of microorganisms. A family of these receptors, the toll-like receptors (TLRs), are also crucial for activating DC to produce cytokines that polarise the T-cell response towards a T helper (Th)1 or Th2 phenotype. This study compared the potential of intact BCG to activate DC with that of the defined TLR4 ligand lipopolysaccharide (LPS) and the TLR9 ligand CpG-oligonucleotide. It was found that all three stimuli efficiently activated normal DC, but cells expressing a mutant TLR4 responded poorly to stimulation with LPS. Importantly, stimulation with BCG induced both IL-12 and IL-10, suggesting subsequent development of a poorly focused T-cell immune response containing both Th1 and Th2 immune function. By contrast, LPS- and CpG-oligonucleotides induced only IL-12, indicating the potential to produce a Th1 response, which is likely to clear cancer most efficiently. Given the toxicity of LPS, our data suggest that CpG-oligonucleotides may be beneficial for intravesical therapy of bladder cancer.
引用
收藏
页码:2312 / 2319
页数:7
相关论文